Edition:
United States

Aptose Biosciences Inc (APTO.OQ)

APTO.OQ on NASDAQ Stock Exchange Capital Market

3.14USD
4:00pm EDT
Change (% chg)

$0.13 (+4.32%)
Prev Close
$3.01
Open
$3.01
Day's High
$3.16
Day's Low
$3.00
Volume
22,381
Avg. Vol
56,684
52-wk High
$4.55
52-wk Low
$1.30

Chart for

About

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates... (more)

Overall

Beta: 2.51
Market Cap(Mil.): $101.18
Shares Outstanding(Mil.): 33.41
Dividend: --
Yield (%): --

Financials

  APTO.OQ Industry Sector
P/E (TTM): -- 169.61 31.56
EPS (TTM): -0.57 -- --
ROI: -136.61 1.42 12.88
ROE: -136.61 0.52 15.04

BRIEF-Aptose Reports Q1 Loss Per Share $0.23

* APTOSE REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2018

May 10 2018

BRIEF-Aptose Biosciences Says Exercises Early Option For Cg-806 License From Crystalgenomics

* APTOSE BIOSCIENCES INC - EXERCISES EARLY OPTION FOR CG-806 LICENSE FROM CRYSTALGENOMICS

May 07 2018

BRIEF-Aptose Biosciences Establishes New At-The-Market Facility

* APTOSE BIOSCIENCES INC SAYS ENTERED INTO AN "AT-THE-MARKET" SALES AGREEMENT WITH CANTOR FITZGERALD & CO

Mar 28 2018

BRIEF-Aptose Reports Qtrly Loss Of $0.12‍​ Per Share

* APTOSE REPORTS RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017

Mar 27 2018

BRIEF-Aptose Biosciences Announces License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology ‍​

* APTOSE BIOSCIENCES - ‍ AGREEMENT PROVIDES OHM ONCOLOGY RIGHTS FOR DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF APL-581

Mar 07 2018

Earnings vs. Estimates